The court sentenced former top managers of Alvitpharm for fraud with cancer drugs.
In the Altai Territory, a judicial body has delivered its verdict against former leading figures of the Alvitpharm organization, concerning a case of deceitful acquisition of costly oncological treatments.
The probe determined that executive director Lyudmila Polyakova and commercial head Yulia Pasichnyak masterminded the distribution of inferior medicinal products, presented as legitimate ones, accompanied by fabricated certificates of genuineness. The monetary harm inflicted upon the regional treasury totaled approximately 30 million rubles. The tribunal condemned the erstwhile executives to incarcerations of six and six and a half years correspondingly, along with monetary penalties of 1.5 million rubles apiece, and mandated the repayment of substantial damages.
The Barnaul Central Regional Court examined a penal case pertaining to deceptive procurement of medications intended for cancer patients. The accused parties are Lyudmila Polyakova, the past director of Alvitpharm LLC, and Yulia Pasichnyak, the firm’s former commercial director. The action against them commenced in April of 2021. Subsequent to the investigation, they faced accusations of large-scale embezzlement exploiting their official capacities (Section 4, Article 159 of the Russian Penal Code) and circulation of substandard pharmaceuticals (Article 238.1 of the Russian Penal Code).
As per the Investigative Department of the Russian Federation for the Altai Territory, the regional Health Ministry, the Altai Oncological Dispensary, and Alvitpharm formalized agreements in 2020 for the provision of two high-priced medications for oncology care. The collective sum of these state contracts neared 30 million rubles.
“These therapeutic agents are deemed critical, and their delivery is supported financially through state funds,” stated Lyudmila Ryazantseva, the designated spokeswoman for the Investigative Committee.
The inquiry brought to light that the company, acting under a government contract, furnished inferior medications, misrepresented as authentic, complemented by fraudulent attestations validating the medications’ authenticity and documentation of origin. Furthermore, law enforcement operatives ascertained that the entity severely contravened storage and transportation standards. Specifically, Alvitpharm neglected to sustain proper temperature regulation.
Altogether, the enterprise acquired 64 ampules of the deficient medicinal substance for 7.2 million rubles and vended them to the Ministry of Health for 16.8 million rubles. The entity similarly dispensed 75 ampules of the medication to the oncology center for 13.2 million rubles, having obtained it from an unreliable vendor for 9.3 million rubles.
The judicial authority discharged the accused under their own assurance of presence pending the completion of the inquest. Their possessions—equity in properties and automobiles valued collectively at 4.1 million rubles—were impounded.
The prior Alvitpharm officers entered a plea of not guilty. Lyudmila Polyakova was assigned six years in a correctional facility of ordinary regime, and Yulia Pasichnyak received an additional term of six months. They were individually assessed fines of 1.5 million rubles and prohibited from holding leadership positions for spans of three and three-and-a-half years, respectively. Moreover, the prosecuting attorney’s application against the defendants for shared and individual recompense was endorsed. Subsequent to the pronouncement of the judgment, the accused were taken into custody within the courtroom. Legal counsel communicated to Kommersant their intent to contest the determination.
